

SARCODO - Evaluation of coagulopathy and endothelial dysfunction as a predictive factor for the severity of SARS-CoV-2/COVID-19 infection

Head :SMADJA David, UMR-S1140 and Biosurgical Research Laboratory (Carpentier Foundation)

Last update : 05/05/2021 | Version : 1 | ID : 73746

General

Identification

Detailed name Evaluation of coagulopathy and endothelial dysfunction as a predictive factor for the severity of SARS-CoV-2/COVID-19 infection

Sign or acronym SARCODO

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CPP2020-04-048b

General Aspects

Medical area Biology
Hematology
Infectious diseases

Study in connection with Covid-19 Yes

Keywords von Willebrand factor, endothelium, COVID-19, haemostasis

Scientific investigator(s) (Contact)

Name of the director SMADJA

Surname David

Address HEGP, Service d'hématologie, 20 rue Leblanc, 75015 Paris

Phone 33613838972

Email david.smadja@aphp.fr

Unit UMR-S1140 and Biosurgical Research Laboratory (Carpentier Foundation)

Organization Inserm

Collaborations

Funding

Funding status Public

Details ANR SARCODO (France Foundation)

Governance of the database

Sponsor(s) or organisation(s) responsible AP-HP

Organisation status Public

Presence of scientific or steering committees No

Additional contact

Email yannick.vacher@aphp.fr

Main features

Type of database

Type of database Others

Specify Clinical and laboratory database

Database recruitment is carried out as part of an interventional study No

Database objective

Main objective Study the coagulopathy, vascular lesion and markers for tissue distress to characterise the exacerbation of patients with COVID-19 and identify patient populations who will develop or experience exacerbation of a thromboembolic or microvascular process, but also require curative anticoagulation.

Inclusion criteria Patients aged at least 18 years
Hospitalised in an intensive care or medicine department for suspected COVID-19.
Patients covered by a social security regime (other than the state welfare scheme)
Patient having been informed of the study and having given their informed consent in writing, or

for whom a family member/trusted person has given their agreement

Population type

Age
Adolescence (13 to 18 years)
Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered General population

Pathology

Gender Male
 Woman

Geography area Regional

French regions covered by the database Île-de-France

Detail of the geography area HEGP and Cochin Hospital

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 2020

Size of the database

Size of the database (number of individuals) [1000-10 000[individuals

Details of the number of individuals 1000

Data

Type of data collected Clinical data
 Biological data

Clinical data (detail) Direct physical measures
 Medical registration

Presence of a biobank Yes

Contents of biobank Whole blood

Plasma
Blood cells isolated
DNA

Procedures

Followed pathology

Promotion and access

Promotion

Link to the document	2020- Debuc et al- SCRR Covid19.pdf
Link to the document	2020- Smadja_Article_Angiopoietin-Covid19-Angiogenesis.pdf
Link to the document	2020- diehl et al- AIC-covid19.pdf
Link to the document	2020- Khider et al-CEC JTH.pdf
Link to the document	2020- Petrazzuolo et al- Oncoimmunology COVID FRP.pdf
Link to the document	2020- bastard et al- Science AutomAb IFN Covid.pdf
Link to the document	2021- Philippe_et_al-Angiogenesis-WILLEBRAND.pdf
Link to the document	2021- Planquette et al- TR- EP Covid.pdf
Link to the document	2020- Guerin et al- SCRR-Article_MultidimensionalProteomicAppro.pdf
Link to the document	2020- Goudot et al- tropo covid-Front Med.pdf

Access